跳至內容

GS-6620

維基百科,自由的百科全書
GS-6620
臨床資料
商品名英語Drug nomenclatureGS-6620
法律規範狀態
法律規範
  • 研究性新藥
識別資訊
  • [(2R,3R,4R,5R)-5-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-4-hydroxy-4-methyl-2-[[[[(2S)-1-oxo-1-propan-2-yloxypropan-2-yl]amino]-phenoxyphosphoryl]oxymethyl]oxolan-3-yl] 2-methylpropanoate
CAS號1350735-70-4
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
化學資訊
化學式C29H37N6O9P
摩爾質量644.6
3D模型(JSmol英語JSmol
  • C[C@@H](C(=O)OC(C)C)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)(C)O)OC(=O)C(C)C)OC4=CC=CC=C4
  • InChI=1S/C29H37N6O9P/c1-17(2)26(36)42-24-22(43-29(15-30,28(24,6)38)23-13-12-21-25(31)32-16-33-35(21)23)14-40-45(39,44-20-10-8-7-9-11-20)34-19(5)27(37)41-18(3)4/h7-13,16-19,22,24,38H,14H2,1-6H3,(H,34,39)(H2,31,32,33)/t19-,22+,24+,28+,29-,45?/m0/s1
  • Key:YAAQYJCOIFNMKX-CVANIGNKSA-N

GS-6620是一種核苷酸類的抗病毒藥物,被開發用於治療丙型肝炎。儘管它在早期測試中顯示出有效的抗病毒作用[1][2],但由於它在腸道中的吸收率低且效果不穩定(無法預測血液中的濃度),未能成功製成口服劑。[3][4]目前進行的研究主要針對其它疾病(如伊波拉出血熱[5][6]的治療。

參考文獻

[編輯]
  1. ^ Cho A, Zhang L, Xu J, Lee R, Butler T, Metobo S, et al. Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. Journal of Medicinal Chemistry. March 2014, 57 (5): 1812–25. PMID 23547794. doi:10.1021/jm400201a. 
  2. ^ Feng JY, Cheng G, Perry J, Barauskas O, Xu Y, Fenaux M, et al. Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrobial Agents and Chemotherapy. 2014, 58 (4): 1930–42. PMC 4023746可免費查閱. PMID 24419349. doi:10.1128/AAC.02351-13. 
  3. ^ Murakami E, Wang T, Babusis D, Lepist EI, Sauer D, Park Y, et al. Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620. Antimicrobial Agents and Chemotherapy. 2014, 58 (4): 1943–51. PMC 4023801可免費查閱. PMID 24419340. doi:10.1128/AAC.02350-13. 
  4. ^ Gentile I, Coppola N, Buonomo AR, Zappulo E, Borgia G. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opinion on Investigational Drugs. September 2014, 23 (9): 1211–23. PMID 24848437. doi:10.1517/13543784.2014.921680. 
  5. ^ De Clercq E. C-Nucleosides To Be Revisited. Journal of Medicinal Chemistry. March 2016, 59 (6): 2301–11. PMID 26513594. doi:10.1021/acs.jmedchem.5b01157. 
  6. ^ De Clercq E. New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chemistry, an Asian Journal. November 2019, 14 (22): 3962–3968. PMID 31389664. doi:10.1002/asia.201900841.